Effect of long and short half-life PDE5 inhibitors on HbA1c levels: a systematic review and meta-analysisResearch in context [PDF]
EClinicalMedicineSummary: Background: Phosphodiesterase 5 (PDE5) inhibitors, owing to their mechanism of action, have been gaining recognition as a potential case of drug repurposing and combination therapy for diabetes treatment.
Joseph Kim +3 more
doaj +2 more sources
Data on the optimisation and validation of a liquid chromatography-high-resolution mass spectrometry (LC-HRMS) to establish the presence of phosphodiesterase 5 (PDE5) inhibitors in instant coffee premixes [PDF]
Data in Brief, 2019 This paper presents the data on the optimisation and validation of a liquid chromatography-high-resolution mass spectrometry (LC-HRMS) to establish the presence of phosphodiesterase 5 (PDE5) inhibitors and their analogues as adulterants in instant coffee
Ahmad Yusri Mohd Yusop +2 more
doaj +2 more sources
Improved survival with phosphodiesterase-5 inhibitor use in men with male-predominant cancers: real-world large database study [PDF]
Frontiers in OncologyIntroductionPhosphodiesterase-5 (PDE5) inhibitors, commonly prescribed for erectile dysfunction, may exhibit immunomodulatory properties by reducing myeloid-derived suppressor cell activity and enhancing T-cell responses.
Daniel Uralov +11 more
doaj +2 more sources
Genetically proxied inhibition of Phosphodiesterase-5 and cancer risks: A drug-target Mendelian randomization analysis [PDF]
Scientific ReportsObservational studies found that phosphodiesterase 5 (PDE5) inhibitors use is linked to both increased and decreased risk of cancer; while the causal relationship remains unclear.
Kefu Tang, Binbin Li, Xi Wu, Meng Wang
doaj +2 more sources
Frontiers in Pharmacology, 2021 Background: Multiple systematic reviews explore the effect of phosphodiesterase type 5 (PDE5) inhibitors on erectile dysfunction (ED), with each study addressing specific outcomes.
Nikolaos Pyrgidis +12 more
doaj +1 more source
PDE5 inhibitor drugs for use in dementia
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2023 Alzheimer's disease and related dementias (ADRD) remain a major health‐care challenge with few licensed medications. Repurposing existing drugs may afford prevention and treatment.
Atticus H. Hainsworth +4 more
doaj +1 more source
Effect of phosphodiesterase type 5 inhibitors on sperm motility and acrosome reaction: An in vitro study [PDF]
Investigative and Clinical Urology, 2021 Purpose: Phosphodiesterase type 5 (PDE5) inhibitors are effective treatments for erectile dysfunction, and several recent studies have reported positive effects of PDE5 inhibitors on semen parameters as well. However, the data are still controversial. We
Seung-Hun Song +8 more
doaj +2 more sources
Recreational Use of Phosphodiesterase 5 Inhibitors and Its Associated Factors among Undergraduate Male Students in an Ethiopian University: A Cross-Sectional Study [PDF]
The World Journal of Men's Health, 2016 Purpose: To assess the prevalence of phosphodiesterase 5 (PDE5) inhibitor use and associated factors among University of Gondar undergraduate students.
Eyob Alemayehu Gebreyohannes +5 more
doaj +1 more source
Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives
Pharmaceuticals, 2023 Phosphodiesterase 5 (PDE5) inhibitors presented themselves as important players in the nitric oxide/cGMP pathway, thus exerting a profound impact on various physiological and pathological processes.
Ahmed K. ElHady +3 more
doaj +1 more source
Sildenafil Citrate-Restored eNOS and PDE5 Regulation in Sickle Cell Mouse Penis Prevents Priapism Via Control of Oxidative/Nitrosative Stress [PDF]
, 2013 Sildenafil citrate revolutionized the practice of sexual medicine upon its federal regulatory agency approval approximately 15 years ago as the prototypical phosphodiesterase type 5 inhibitor indicated for the treatment of male erectile dysfunction.
Berkowitz, DE +5 more
core +7 more sources